GlassScriptPhysician profile
Kristina Hool
NPI 1154556702
$1,340.56
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $312 · 2023: $1,012 · 2024: $17.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,028.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $168.88 | 2022-2023 | Calquence, Lynparza, Imfinzi |
| Janssen Biotech, INC. | $132.01 | 2022-2023 | Imbruvica, Erleada |
| Seagen INC. | $100.53 | 2022-2023 | Adcetris, Padcev |
| Lilly USA, LLC | $82.69 | 2023 | Jaypirca, Retevmo, Verzenio |
| Exelixis INC. | $70.55 | 2022-2023 | Cabometyx |
| Incyte Corporation | $66.62 | 2023 | Jakafi |
| Pfizer INC. | $65.46 | 2023 | |
| Jazz Pharmaceuticals INC. | $60.48 | 2022-2023 | |
| Genzyme Corporation | $59.63 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $56.03 | 2023 | |
| Amgen INC. | $55.19 | 2022-2023 | Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $52.92 | 2022-2023 | Opdivo |
| Daiichi Sankyo INC. | $52.06 | 2022-2024 | Enhertu, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $38.83 | 2023 | Ninlaro |
| Bayer Healthcare Pharmaceuticals INC. | $35.74 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $30.01 | 2022-2023 | |
| Pharming Healthcare, INC. | $26.82 | 2023 | Ruconest |
| Deciphera Pharmaceuticals INC. | $23.65 | 2023 | Qinlock |
| Servier Pharmaceuticals LLC | $22.19 | 2023 | |
| Emd Serono, INC. | $20.34 | 2023 | Bavencio |
| Abbvie INC. | $19.51 | 2023 | |
| Adaptive Biotechnologies Corporation | $18.64 | 2023 | Clonoseq |
| Sumitomo Pharma America, INC. | $18.07 | 2023 | Orgovyx |
| Astellas Pharma US INC | $17.77 | 2023 | Xtandi |
| Merck Sharp & Dohme LLC | $16.67 | 2023 | Lynparza, Keytruda |
| Karyopharm Therapeutics INC. | $15.48 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $13.79 | 2023 | Imbruvica |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristina Hool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.